Evidence map›Paper›PMID 41272884›Full record

ArticleJournal of medical case reports2025

Clonal identification and homology differentiate primary central nervous system lymphoma from non-central nervous system lymphoplasmacytic lymphoma: a case report.

Yuko Tanaka, Nahoko Furuya, Seiichi Okabe, Seiichiro Yosizawa, Seiichiro Katagiri, Michiyo Asano, Tamiko Suguro, Mitsuru Moriyama, Akiko Yamada, Shunsuke Ohtsuki and 10 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Yuko TanakaDepartment of Hematology, Tokyo Medical University, 6-7-1, Nishi-Shinjuku, Shinjuku-Ku, Tokyo, Japan. yukois9@tokyo-med.ac.jp.ORCID http://orcid.org/0000-0002-1114-8188
Nahoko FuruyaDepartment of Hematology, Tokyo Medical University, 6-7-1, Nishi-Shinjuku, Shinjuku-Ku, Tokyo, Japan.
Seiichi OkabeDepartment of Hematology, Tokyo Medical University, 6-7-1, Nishi-Shinjuku, Shinjuku-Ku, Tokyo, Japan.
Seiichiro YosizawaDepartment of Hematology, Tokyo Medical University, 6-7-1, Nishi-Shinjuku, Shinjuku-Ku, Tokyo, Japan.
Seiichiro KatagiriDepartment of Hematology, Tokyo Medical University, 6-7-1, Nishi-Shinjuku, Shinjuku-Ku, Tokyo, Japan.
Michiyo AsanoDepartment of Hematology, Tokyo Medical University, 6-7-1, Nishi-Shinjuku, Shinjuku-Ku, Tokyo, Japan.
Tamiko SuguroDepartment of Hematology, Tokyo Medical University, 6-7-1, Nishi-Shinjuku, Shinjuku-Ku, Tokyo, Japan.
Mitsuru MoriyamaDepartment of Hematology, Tokyo Medical University, 6-7-1, Nishi-Shinjuku, Shinjuku-Ku, Tokyo, Japan.
Akiko YamadaDepartment of Hematology, Tokyo Medical University, 6-7-1, Nishi-Shinjuku, Shinjuku-Ku, Tokyo, Japan.
Shunsuke OhtsukiDepartment of Hematology, Tokyo Medical University, 6-7-1, Nishi-Shinjuku, Shinjuku-Ku, Tokyo, Japan.
Hiroaki FujimotoDepartment of Hematology, Tokyo Medical University, 6-7-1, Nishi-Shinjuku, Shinjuku-Ku, Tokyo, Japan.
Daigo AkahaneDepartment of Hematology, Tokyo Medical University, 6-7-1, Nishi-Shinjuku, Shinjuku-Ku, Tokyo, Japan.
Moritaka GotohDepartment of Hematology, Tokyo Medical University, 6-7-1, Nishi-Shinjuku, Shinjuku-Ku, Tokyo, Japan.
Maki TanigawaDepartment of Anatomic Pathology, Tokyo Medical University, Shinjuku-Ku, Tokyo, Japan.
Jun MatubayashiDepartment of Anatomic Pathology, Tokyo Medical University, Shinjuku-Ku, Tokyo, Japan.
Shinjiro FukamiDepartment of Neurosurgery, Tokyo Medical University, Shinjuku-Ku, Tokyo, Japan.
Michihiro KohnoDepartment of Neurosurgery, Tokyo Medical University, Shinjuku-Ku, Tokyo, Japan.
Toshitaka NagaoDepartment of Anatomic Pathology, Tokyo Medical University, Shinjuku-Ku, Tokyo, Japan.
Naoya NakamuraDepartment of Pathology, Tokai University School of Medicine, Isehara-City, Kanagawa, Japan.
Akihiko GotohDepartment of Hematology, Tokyo Medical University, 6-7-1, Nishi-Shinjuku, Shinjuku-Ku, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLymphoplasmacytic lymphoma/Waldenström macroglobulinemia rarely transforms into diffuse large B-cell lymphoma, and there have been no reports of cases proving clonal identity when presenting as primary central nervous system lymphoma. There are many unclear aspects regarding the mechanism by which lymphoplasmacytic lymphoma/Waldenström macroglobulinemia infiltrates the central nervous system and transforms, as well as the treatment methods for the transformed lymphoma. CASE PRESENTATION: A 49-year-old Asian Japanese male was emergently transported due to loss of consciousness, revealing a tumorous lesion in the brain. He was diagnosed with primary central nervous system lymphoma following an endoscopic biopsy and treated with immunochemotherapy included high-dose methotrexate. During the second course of immunochemotherapy, a computed tomography scan conducted to investigate bilateral lower leg edema revealed tumorous lesions in both lower legs. A biopsy of the thigh node specimen was diagnosed as lymphoplasmacytic lymphoma. When high-dose methotrexate including immunochemotherapies was finished, the lymphoma lesions in central nervous system had disappeared. However, the symptoms of bilateral lower leg edema were prominent because of remaining the bilateral thigh nodes, so additional immunochemotherapy for lymphoplasmacytic lymphoma/Waldenström macroglobulinemia was administered, resulting in complete remission of the lymphoplasmacytic lymphoma/Waldenström macroglobulinemia as well. primary central nervous system lymphoma, and he has maintained both lymphomas for 4 years. The myeloid differentiation factor 88 (MYD88) gene mutation was detected in primary central nervous system lymphoma and lymphoplasmacytic lymphoma/Waldenström macroglobulinemia lymphoma cells. The same clonal origin of primary central nervous system lymphoma and lymphoplasmacytic lymphoma/Waldenström macroglobulinemia was confirmed according to homology in a region of the immunoglobulin heavy chain V (IGHV) gene. On the basis of the characteristics of primary central nervous system lymphoma and lymphoplasmacytic lymphoma/Waldenström macroglobulinemia, we speculated that the lymphoplasmacytic lymphoma/Waldenström macroglobulinemia lymphoma cells had already invaded the central nervous system, a condition called Bing-Neel syndrome, and transformed into primary central nervous system lymphoma cells after a certain period.

conclusionIt was revealed that the lymphoma cells of both lymphoplasmacytic lymphoma/Waldenström macroglobulinemia and primary central nervous system lymphoma derived from a common cell possessing MYD88. The utility of adding chemotherapy for low-grade lymphoma in addition to therapy for primary central nervous system lymphoma is not clear. While lymphoplasmacytic lymphoma is a low-grade lymphoma that does not always require chemotherapy, combining treatment for lymphoplasmacytic lymphoma and primary central nervous system lymphoma may contribute to the effectiveness of both treatments.

Indexed as

Central Nervous System NeoplasmsWaldenstrom MacroglobulinemiaDiagnosis, DifferentialHumansMaleMethotrexateMiddle AgedMyeloid Differentiation Factor 88Tomography, X-Ray ComputedMethotrexateMYD88 protein, humanMyeloid Differentiation Factor 88Homology of IGHVLymphoplasmacytic lymphomaPrimary central nervous system lymphomaWaldenström macroglobulinemia

Identifiers

PMID41272884
PMCPMC12639785

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.